

Epigenetics, DNA Methylation, and Chromatin Modifying Drugs

Moshe Szyf

Department of Pharmacology and Therapeutics, McGill University, Montréal, Quebec H3G 1Y6, Canada; email: mszyf@pharma.mcgill.ca

Annu. Rev. Pharmacol. Toxicol. 2009. 49:243–63

First published online as a Review in Advance on October 13, 2008

The *Annual Review of Pharmacology and Toxicology* is online at pharmtox.annualreviews.org

This article's doi:
10.1146/annurev-pharmtox-061008-103102

Copyright © 2009 by Annual Reviews.
All rights reserved

0362-1642/09/0210-0243\$20.00

Key Words

DNA methylation, chromatin structure, histone deacetylase inhibitors, methyltransferase, demethylase, epigenetics

Abstract

Evidence is emerging that several diseases and behavioral pathologies result from defects in gene function. The best-studied example is cancer, but other diseases such as autoimmune disease, asthma, type 2 diabetes, metabolic disorders, and autism display aberrant gene expression. Gene function may be altered by either a change in the sequence of the DNA or a change in epigenetic programming of a gene in the absence of a sequence change. With epigenetic drugs, it is possible to reverse aberrant gene expression profiles associated with different disease states. Several epigenetic drugs targeting DNA methylation and histone deacetylation enzymes have been tested in clinical trials. Understanding the epigenetic machinery and the differential roles of its components in specific disease states is essential for developing targeted epigenetic therapy.

HDAC: histone deacetylase

HAT: histone acetyltransferase

HDACis: HDAC inhibitors

TSA: trichostatin A

SAHA: suberoylanilide hydroxamic acid

INTRODUCTION: EPIGENETICS AND HUMAN DISEASE

Changes in the normal program of gene expression are the basis for several human diseases. The genome is programmed by the epigenome. The epigenome consists of the chromatin and its modifications, as well as a covalent modification of cytosines residing at the dinucleotide sequence CG in DNA by methylation (1). Recently, a new level of epigenetic regulation by small noncoding RNAs, termed microRNAs, has been discovered (2). A large number of loci in the human genome encode noncoding RNAs, which are processed to short RNAs and target specific genes for silencing. microRNAs regulate gene expression at different levels; they silence chromatin, degrade mRNA, and block translation. microRNAs play an important role in cancer (3) and potentially play an important role in behavioral pathologies, as well (4). Additional forms of noncoding RNA are involved in programming gene expression. For example, the Air RNA regulates Igf1R gene expression in a manner dependent on the parental origin of the allele (5), and Xist RNA is involved in inactivation of the X chromosome (6). microRNA expression is regulated by epigenetic factors such as DNA methylation and chromatin structure (7).

CHROMATIN MODIFYING DRUGS IN CLINICAL DEVELOPMENT

DNA is wrapped around a protein-based structure termed chromatin. The basic building block of chromatin is the nucleosome, which is formed of an octamer of histone proteins. There are 5 basic forms of histone proteins, H1, H2A, H2B, H3, and H4 (8), as well as other minor variants, which are involved in specific functions such as DNA repair and gene activation (9). The octamer structure of the nucleosome is composed of a H3-H4 tetramer flanked on either side with a H2A-H2B dimer (8). The N-terminal tails of these histones are extensively modified by methylation (10), phosphorylation, acetylation (11), sumoylation (12), and ubiquitination (13). The state of modification of these tails plays an important role in defining the accessibility of the DNA to the transcription machinery. Bidirectional enzymatic machineries modify the chromatin. This offers significant opportunities for developing drugs that can affect the state of chromatin in both directions. The main challenge in using epigenetic modulators for therapy is specificity.

HISTONE DEACETYLASE INHIBITORS AND THEIR ROLE IN CANCER THERAPY

Histone acetylation is a global mark of gene activity. Histone deacetylases (HDACs) remove histones and histone acetyl transferases (HATs) acetylate histones. The most advanced chromatin modification targeted drugs are HDAC inhibitors (HDACis). There is a vast literature demonstrating the involvement of HDACs in suppressing critical genes in cancer (14, 15). HDACis are now being considered as potential therapeutics for mental pathologies, as well (16).

HDAC inhibitors fall into five different structural groups that are currently at varying stages of development. The classic HDACis, trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), are hydroxamate based. They inhibit class 1 and class 2 HDACs. SAHA is the first clinically approved HDACi. A second group includes hydroxamate based HDACis (LBH589, PXD101) that are currently in different stages of clinical development and inhibit class 1 and class 2 HDACs. The third group are aliphatic based and also inhibit class 1 and class 2 HDACs. This group includes sodium butyrate, one of the earliest HDAC inhibitors, as well as the mood stabilizer and antiepileptic valproic acid. The fourth group includes a cyclic peptide based HDACi (FK228) that inhibits class 1 and class 2 HDACs. The fifth group are benzamide based HDACis that inhibit classes 1, 2, and 3 HDACs. An interesting example is MGCD0103, which showed

isotypic specificity against class 1 HDACs and a broad spectrum of antitumor activity (17). HDAC inhibitors have exhibited anticancer activity in preclinical tumor models and in phase 1 and phase 2 clinical trials [for a review, see (18)], and the first HDACi Vorinostat (SAHA) was recently approved for clinical use in cutaneous T-cell lymphoma (19). Vorinostat was safe and effective at an oral dose of 400 mg/day with an overall response rate of 30 to 31% in refractory advanced patients with CTCL (19). The HDAC1 isotypic specific MGCD0103 is now being tested in phase 1 and phase 2 clinical trials in solid and hematological tumors and has shown some clinical response (20–22). Several novel HDACis are at different stages of preclinical development.

The putative mechanism of action of HDACis in cancer is as follows: Blockage of HDACs tilts the balance of acetylation–deacetylation reactions toward acetylation. This results in hyperacetylation of histone tails and induction of genes that suppress the cancer phenotype such as tumor suppressor genes and metastasis- and invasion-inhibitory genes. A well-characterized example is the tumor suppressor *P21* that is induced in response to treatment with TSA (23). Another example is *E CADHERIN*, a gene that blocks mesenchymal to epithelial transition and cell invasiveness and is induced by TSA (24). HDACis block multiple biological steps in cancer progression in cultured cancer cells, including cell cycle arrest (25), apoptosis (26), epithelial to mesenchymal transition (27), and invasion (28).

All the known HDACis block one class or several classes of HDACs and thus should have a global effect on gene expression. Nevertheless, comprehensive microarray gene expression experiments reveal that only a fraction of the transcriptome is activated or suppressed with HDAC inhibition (29–32). HDACs and HATs are targeted to specific genes. HDACis will affect only genes that are associated with HDACs and are also targets of HATs. Thus, the specific gene expression response to an HDACi will be determined by the profile of distribution of HDACs and HATs in the genome. Oncogenic pathways target HDACs to specific genes. For example, SNAIL targets HDAC1/2 to the promoter of *E CADHERIN* (33). The relatively specific effects of HDACi on cancer cell growth suggest that critical cancer genes are HDAC bound and HAT targeted.

There are 4 defined phylogenic classes of HDACs. Specificity of HDACis might increase if the isotypes of HDACs involved in cancer are specifically targeted. Evidence points to the involvement of class 1 HDACs, HDAC1 and HDAC3, in several types of cancer (34). A recent example of an isotypic-specific drug is MGCD0103, which has high affinity to HDAC1 and has shown excellent activity in vitro and in vivo (17) in tumor models and is now in clinical trials (21). However, even isotypic-specific inhibitors that target HDAC1 act on an enzyme with multiple genomic targets.

HISTONE DEACETYLASE INHIBITORS AND THEIR ROLE IN MENTAL HEALTH

Chromatin acetylation and memory were shown to be impaired in CBP knockout mice, which suggests a role for acetylation in memory formation (35). The fact that valproic acid, a long established antiepileptic and mood stabilizer, is also a HDAC inhibitor (36) alludes to a possible role for HDACis in treating certain mental conditions such as schizophrenia. Valproic acid has had some effect alleviating psychotic agitation as an adjunct to antipsychotics in schizophrenia (37, 38). HDACis were shown to improve memory and induce dendritic sprouting in a transgenic mouse model of neurodegeneration, which suggests that HDACis might be of use in treating neurodegeneration and memory loss, as well (39). Although biological and behavioral effects of HDACis in the brain are somewhat characterized, their specific gene targets and their function in mental pathologies are not well delineated. Nevertheless, the limited clinical and animal data suggest a potentially important role for HDACis in treatment of mental disorders.

HMTase: histone methyltransferase

DNMT: DNA methyltransferase

Recent clinical developments are focusing on schizophrenia. Experiments with a novel HDACi from the benzamide class N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide derivative (MS-275) in mice resulted in brain region-specific induction of acetylation in the frontal cortex at two genes involved with schizophrenia pathogenesis, *reelin* and *gad(67)* (16). Valproic acid was shown to induce the expression of *reelin*, which was silenced by methionine treatment in mice (40). These studies raise the possibility that treatment of schizophrenics with an HDACi might cause activation of expression of critical genes such as *REELIN*, and could reverse the course of this disease (41). Several clinical trials tested valproate as an adjunctive therapy to antipsychotics in schizophrenia (38, 42, 43). There are indications that valproate might improve violent episodes in a subset of schizophrenia patients (42), and might, in combination with antipsychotics, have an effect on euphoric mania (38) and features of manic symptomatology in bipolar disorders (38). Further clinical trials are needed with valproate and with more potent and selective HDACis to methodically test their therapeutic potential in mental pathologies. Isotypic-specific HDACis might enhance the efficacy and potency of the treatment and reduce its toxicity.

HDAC INHIBITORS AND THEIR ROLE IN OTHER HEALTH CONDITIONS

HDACis are potential therapeutics for other health conditions. One interesting area is transplantation. A special subset of T cells, regulatory T cells (Tregs), control and maintain transplant tolerance by suppressing immune responsiveness to the transplant. HDACis activate the transcription factor *FOXP3*, which plays a cardinal role in the immunosuppressive function of Treg cells (44). HDAC9 has proven particularly important in negatively regulating *FOXP3*-dependent suppression (44), thus raising the attractive possibility that isotypic-specific HDAC9 inhibitors might serve as excellent agents for suppressing the antitransplant response in transplantation therapy. In addition, it might be potentially important in suppression of other autoimmune and proinflammatory conditions. Recent preclinical trials with SAHA in the rhesus macaque demonstrated efficacy in primates in induction of Treg function (45).

Other candidates for HDACis are metabolic diseases such as type 2 diabetes. The critical glucose transporter, GLUT4, response to exercise is regulated by HDAC5. Activation of GLUT4 through inhibition of HDAC5 might be an interesting approach to type 2 diabetes (46). Because HDACi treatment of type 2 diabetes is anticipated to be chronic and long-term, it is especially critical to focus on isotypic-specific inhibitors in order to limit systemic toxicity.

HISTONE METHYLTRANSFERASE INHIBITORS

A new area of potential interest is the development of histone methyltransferase (HMTase) inhibitors. H3K9Me2 histone is a hallmark of gene silencing and was shown to mark silenced tumor suppressor genes (47–49). H3K27 methylation, which is targeted by the polycomb group protein and histone methyltransferase EZH2, is another interesting target for inhibition (**Figure 1**). EZH2 associates with DNA methyltransferases (DNMTs) in silencing of tumor suppressor genes (50). HMTase inhibitors could be used therapeutically to activate silenced tumor suppressor genes. Two HMTase inhibitors were recently described. The fungal mycotoxin chaetocin, which belongs to the class of 3–6 epidithio-diketopiperazines (ETPs), specifically inhibits the *Drosophila* HMTase dSU(VAR)3–9 and its human homolog (51). A small-molecule inhibitor of G9a histone methyltransferase was reported last year and was shown to block H3K9Me2 in vitro and in cell culture (52). However, it is not known whether these compounds have anticancer activity or systemic toxicity.




Figure 1

Interaction of histone methyltransferase and DNA methyltransferases (DNMTs) in methylation of tumor suppressor genes. Tumor suppressor genes are marked by EZH2 binding and K27 methylation (K27-M). Increase in DNMT expression as a result of activation of oncogenic pathways such as RAS or RB knockdown increases cellular levels of DNMT1, which is then recruited to EZH2 sites in the genome, resulting in methylation of EZH2-associated DNA (circled M). This illustrates the tight correlation between chromatin and DNA modifications. HMTase inhibitors should cause DNA demethylation as well.

Another interesting group of targets are histone demethylases (53, 54). H3K4Me2 is a hallmark of active genes. Because the state of histone methylation is a balance of methylation and demethylation reactions, inhibition of H3K4 demethylase would result in increased H3K4 histone methylation and activation of genes, including potential tumor suppressor genes. A candidate target is the histone, lysine-specific demethylase 1 (LSD1), that demethylates H3K4Me2. Novel biguanide and bisguanidine polyamine analogues were shown to inhibit LSD1, a homologue of polyamine oxidase, and activate multiple aberrantly silenced genes in colorectal cancer cells (55). Nonselective monoamine oxidase inhibitors such as tranylcypromine, which were used as antidepressive medication in psychiatry, were also found to be LSD1 inhibitors (56). It is possible that LSD1 inhibition is involved in the mechanism of action of antidepressive agents. It is tempting to speculate that selective inhibitors of LSD1 might be effective as antidepressants, as well.

DNA METHYLATION PATTERNS

A major element of epigenetic regulation in vertebrates is the pattern of distribution of a covalent modification of cytosines by methylation in the genome. The primary methylated sequence in vertebrates is composed of only two bases, the di-nucleotide sequence CG (57). Only <80% of the methylatable CG population is methylated. Different CG sites are methylated in different tissues, creating a pattern of methylation that is gene and tissue specific (57). This pattern creates a layer of information that confers upon a genome its specific cell type identity. The DNA methylation pattern is copied by independent enzymatic machinery, the DNMT (58). DNA methylation patterns in vertebrates are distinguished by their tight correlation with chromatin structure. Active regions of the chromatin, which enable gene expression, are associated with hypomethylated DNA, whereas hypermethylated DNA is packaged in inactive chromatin (58).

Mechanisms of Silencing of Gene Expression by DNA Methylation

DNA methylation is a highly effective mechanism for silencing of gene expression in vertebrates and plants. DNA methylation silences gene expression either by interfering with the binding of

LSD1: lysine-specific demethylase 1

MBD: methylated DNA binding domain

SAM: S-adenosyl-L-methionine

transcription factors (59, 60), or by attracting methylated DNA-binding proteins (MBDs) such as MeCP2 (61). MeCP2 recruits other proteins such as SIN3A and histone modifying enzymes, which leads to formation of a closed chromatin configuration and silencing of gene expression (61). Several methylated DNA-binding proteins such as MeCP2, MBD1, MBD2, and MBD3 suppress gene expression by a similar mechanism (62–64). MBD3 does not bind directly methylated DNA, but it associates with the NurD complex that contains MBD2 as the methylated DNA-binding factor (65). Certain MBDs have other enzymatic activities. MBD4 is a thymidine glycosylase (66), and MBD2 was suggested to bear demethylase activity (67–71), although this is highly contested.

DNA Methyltransferases

The DNA methylation reaction is catalyzed by DNMT (58). Methylation of DNA occurs immediately after replication by a transfer of a methyl moiety from the donor S-adenosyl-L-methionine (SAM, or AdoMet) in a reaction catalyzed by DNMT. Three distinct phylogenic DNA methyltransferases were identified in mammals. DNMT1 shows preference for hemimethylated DNA *in vitro*, which is consistent with its role as a maintenance DNMT, whereas DNMT3a and DNMT3b methylate unmethylated and methylated DNA at an equal rate, which is consistent with a *de novo* DNMT role (72). It is clear, however, that this classic distinction between *de novo* and maintenance DNMT doesn't always apply. Both classes of enzymes participate in both *de novo* and maintenance methylation, and DNA methylation is a targeted process.

Is DNA Methylation a Reversible Reaction?

The most controversial issue in the DNA methylation field is the question of whether the DNA methylation reaction is reversible (73). Dynamic reversibility is essential for life-long responsiveness of the DNA methylation pattern to drugs. There is a long list of data from both cell culture and early mouse development supporting the hypotheses that active methylation occurs in embryonal and somatic cells, and that a dynamic, reversible DNA methylation pattern is involved in memory in the brain (74), as well as in an estrogen induced gene (75).

Several enzymatic activities were proposed to cause DNA demethylation. A G/T mismatch repair glycosylase functions as a 5-methylcytosine DNA glycosylase, recognizes methyl cytosines, and cleaves the bond between the sugar and the base. The abasic site is then repaired and replaced with a nonmethylated cytosine resulting in demethylation (76). An additional protein with similar activity was recently identified, the methylated DNA binding protein 4 (MBD4) (77). MBD2b (a shorter isoform of MBD2) was shown to directly remove the methyl group from methylated cytosine in methylated CpGs (78), but this was contested by several groups (63). GADD45A, a damage response protein, was proposed to trigger active DNA demethylation through a repair-mediated process (79). However, this was also contested by a later study (80). More recently, it was proposed that the DNA methyltransferase DNMT3A acts as a demethylase, possibly through a mechanism that involves deamination (81).

BILATERAL RELATIONSHIP BETWEEN CHROMATIN STRUCTURE AND DNA METHYLATION

Correlation Between Chromatin and DNA Methylation States

The two components of the epigenome, DNA methylation and chromatin, are tightly correlated (**Figures 1** and **2**). More than three decades ago, Cedar & Razin showed that inactive chromatin is




Figure 2

Interrelation between chromatin modifying drugs and DNA methylation. Histone deacetylase inhibitors (HDACis) cause acetylation of target genes, which facilitates demethylation. This could serve as a way to demethylate genes in the brain, where 5-aza-cytidine (5-azaC), a replication-dependent DNA methylation inhibitor, would not be functional. Acetylation (Ac); methylcytidine (M).

enriched with hypermethylated DNA and that active chromatin is associated with hypomethylated DNA (58). These correlations were confirmed by detailed analyses of specific genes, as well as genome-wide ChIP-on-chip analyses. The relationship between chromatin and DNA methylation is bilateral (82).

Implications of the Interrelationship of Chromatin and DNA Methylation on the Use of Chromatin Modifying Drugs

The interrelation between chromatin state and DNA methylation suggests that there is a crosstalk between drugs targeting chromatin and those targeting DNA methylation. This could be utilized therapeutically. For example, because HDACis not only affect histone acetylation but also facilitate replication-independent DNA demethylation (70), they could be utilized to induce demethylation in post mitotic nondividing tissues such as brain or heart (**Figure 2**). Catalytic inhibitors of DNMT1 such as 5-aza-cytidine (5-azaC) or Zebularine need to be incorporated into DNA; only then do they inhibit DNMT during passage of the replication fork. Indeed, valproate, the antiepileptic drug that is also an HDACi, induces replication-independent demethylation (69, 83) in cell culture and demethylation of the *reelin* gene in mouse brain in vivo (84).

HISTONE MODIFYING ENZYMES AND RECRUITMENT OF DNA METHYLTRANSFERASES AND DEMETHYLASES TO SPECIFIC GENES

Specific DNA methylation patterns could be directed by chromatin modification. It is now well established that histone modification enzymes interact with DNA methylating enzymes and recruit DNA methylation activity to specific targets. A growing list of histone modifying enzymes such as HDAC1 and HDAC2 have been shown to interact with DNMT1, DNMT3a, the histone methyltransferases SUV3-9, EZH2, and PRC2/3, a member of the multi-protein polycomb complex that methylates H3 histone at the K27 residue (85–88), as well as the heterochromatin protein HP1, which binds H3-K9 methylated histones (89). The methylated DNA binding protein MeCP2 interacts with the HMT SUV3-9 (87).

One of the most important links between chromatin and DNA methylation is the association of EZH2 HMTase, methylation of H3-histones at K27 residues, and DNA methylation of tumor suppressor genes (**Figure 2**). A survey of CG islands methylated in lung cancer revealed that they were also PcG EZH2 targets (90). Thus, sites bound by EZH2 are poised to become methylated, but in normal cells the level of DNMT1 keeps the EZH2 targets unmethylated. In the process of tumorigenesis, DNMT1 levels are induced by activation of several oncogenic pathways and

5-azaC:
5-aza-cytidine

silencing of tumor suppressor pathways (91–95). It is therefore anticipated that EZH2 inhibitors will trigger selective loss of methylation of tumor suppressor genes.

Similar to DNA methylation, demethylation is targeted to genes by chromatin modification changes. Transcription factors recruit HATs to specific genes. This triggers gene-specific acetylation and recruitment of RNApolIII to the gene, which is followed by demethylation (96). There are examples in the literature indicating that transcription factors such as *NF-κB* (97) and NGFI-A (98) are required for replication-independent active demethylation.

In summary, DNA methylation pattern and chromatin structure are found in a dynamic balance. This balance is required to maintain the homeostasis of epigenetic information. A change in either of these parameters would trigger a change in the DNA methylation state.

DNA METHYLATION PHARMACOLOGY

DNA methylation could be modified pharmacologically. By modification of DNA methylation, it would be possible to alter gene expression programs, including those for pathological gene expression. There are potentially multiple diseases that are candidates for DNA methylation therapy. The critical issues are: understanding the aberrations in methylation involved in the disease, the complexity of the DNA methylation machinery, and the multiple interactions of the DNA methylation machinery with other cellular machineries.

Aberrations of DNA Methylation Patterns and DNA Methylation Machinery in Cancer

Cancer was the first disease for which DNA methylation was proposed as a therapeutic target (99). The first DNA methylation inhibitor 5-azaC (or 5AC) and its deoxy analog 5-azadC (or DAC) (100) were recently approved by the FDA for treatment of myelodysplastic syndromes (MDS) (101) (see **Figure 3**). Three types of aberration in the DNA methylation machinery occur in cancer: hypermethylation of tumor suppressor genes, aberrant expression




Figure 3

Mechanism of action of 5-aza-cytidine (5-azaC) and 5-azadC. 5-azadC is a prodrug, which needs to be phosphorylated by cellular cytidine kinases to the triphosphate nucleotide 5-azadCTP. 5-azadCTP is incorporated into DNA and traps the DNA methyltransferase (DNMT) in the progressing fork, resulting in passive demethylation of the nascent strand. Methylated CGs (red circles); unmethylated CGs (purple circles).




Figure 4

Epigenetic changes in cancer involve both methylation of tumor suppressor genes and demethylation of prometastatic genes. The process of gene activation involves participation of histone acetyl transferases (HATs), histone demethylases, and possibly DNA demethylases. The process of gene inactivation involves participation of DNA methyltransferases (DNMTs), histone deacetylases (HDACs), and histone methyltransferases (HMTases). Tumor suppressors could be activated by either HDACi or DNMT inhibitors, however, it is possible that the DNA demethylation would activate prometastatic genes. Several agents were shown to suppress prometastatic genes in culture and in vivo: S-adenosyl-L-methionine (SAM), 5'-methylthioadenosine (MTA), and a methylated DNA binding domain 2 (MBD2) antisense oligonucleotide.

of DNMT1 and other DNMTs, and hypomethylation of unique genes and repetitive sequences (102–104). It is important to consider all three when designing therapeutic strategies targeting DNA methylation (**Figure 4**).

Mechanism of Action of DNMT1 Inhibitors

The expression of DNMT1 is tightly regulated with the state of cell growth by transcriptional and posttranscriptional mechanisms (105, 106). Several oncogenic pathways lead to overexpression of DNMT1 through transcriptional and posttranscriptional control of DNMT1 (91–93, 107). Deregulation of the proper cell-cycle coordinated expression of *DNMT1* causes cellular transformation (107). Overexpression of *DNMT1* in nontransformed cells leads to cellular transformation (108), whereas knockout of *dnmt1* protects mice from colorectal cancer (109). Taken together, these data support the idea that inhibition of DNMT1 should be a reasonable strategy for anticancer therapeutics. The anticancer effects of DNMT1 inhibition were demonstrated pharmacologically using antisense oligonucleotide inhibitors (110, 111), and genetically using *dnmt1*^{-/-} mice (109).

In order to properly design and utilize therapeutic strategies that involve DNMT1 inhibition, it is essential to understand why DNMT1 transforms cells and why DNMT1 inhibition blocks tumor growth. DNMT1 is an enzyme that methylates DNA. The commonly accepted and attractively straightforward model is that DNMT1 inhibition causes loss of methylation during DNA synthesis and, as a result, aberrantly methylated tumor suppressor genes are activated, arresting tumor growth. However, knockdown of DNMT1 by siRNA or antisense oligonucleotides blocks the growth of cancer cells by mechanisms independent of DNA methylation through induction of tumor suppressor genes (112). This triggers a DNA damage response and inhibition of DNA replication (113). It is plausible, therefore, that DNMT1 transforms cells by a mechanism independent of DNA methylation and that targeting the DNA methylation-independent functions of DNMT1 will have a strong anticancer growth effect (**Figure 4**).

DNA Methylation Inhibitors and DNMT1 Modulators

The three most commonly used catalytic inhibitors of DNMTs are the nucleoside analogs 5-azaC, 5-azaCdR, and Zebularine. The mechanism of action of these inhibitors is somewhat unique. They

are first phosphorylated to the triphosphate nucleotide and incorporated into DNA during DNA synthesis (**Figure 3**). DNMT1 forms a covalent bond with the carbon at position 6 of the cytosine, as well as at the 5-aza-cytosine ring in DNA. Under normal conditions, the enzyme transfers the methyl group from SAM to the 5' carbon position of the cytosine ring. This enables the release of the enzyme from its covalent bond with cytosine. When a 5'-aza-cytosine ring replaces cytosine in the DNA, the methyl transfer does not take place and the DNMT is trapped on the DNA (114). The replication fork progresses in the absence of DNMT, resulting in passive loss of DNA methylation in the nascent strand but not the template. Zebularine is a nucleoside analog that, unlike 5-azaC, is chemically stable and orally bioavailable. Zebularine was originally identified as a cytidine deaminase inhibitor (115). Its mechanism of action is predicted to be similar to that of 5-azaC. This compound exhibits DNA demethylation activity and shows reduced potency and toxicity in comparison to 5-azaC.

Because both 5-azaC and Zebularine need to be incorporated into DNA to trap DNMT, they might have additional nonspecific toxicities that are a result of the trapping of DNMT1 onto DNA, and perhaps the trapping of other DNA binding proteins, as well (116). Non-nucleoside-based inhibitors of DNMT1 that inhibit DNMT catalytic activity without incorporation into DNA are therefore of much interest. Such a compound was described, but its efficacy and potency in whole animals and humans are unclear (117).

Other commonly used drugs were shown to bring about demethylation. For example, procainamide, a widely used antiarrhythmic drug, inhibits DNMT activity and promotes hypomethylation (118, 119). Recently, analogues of procainamide were synthesized and one lead was reported to inhibit DNMT1 and to cause global hypomethylation (120). Hydralazine, an antidiuretic, induces hypomethylation (118). Valproic acid, a widely used antiepileptic and mood stabilizer, was shown to cause demethylation (69, 83). These data raise the concern that other heavily used drugs affect the DNA methylation pattern and thus can promote the expression of disease-promoting genes (121). Future drug safety tests should include measures of DNA demethylation (121).

Clinical Trials with DNA Methylation Inhibitors

Several clinical trials have been launched with a nucleoside-analog pan DNMT inhibitor 5-azaC and its deoxy analog 5-deoxycytidine (DAC). Responses with tolerable adverse effects were reported in clinical trials in hematological malignancies, especially in myelodysplastic syndrome (MDS) (122). However, there was no significant success reported in solid tumors (123). The weak response of solid tumors might result from pharmacokinetic issues such as delivery problems, as well as dosing and scheduling. Different strategies for combining 5-azaC with other chemotherapeutic agents or chromatin modifiers such as HDACis are now being tested and might be effective in solid tumors (124).

Basic questions regarding the mechanism of action of 5-azaC need to be answered. Although the basic hypothesis is that 5-azaC causes demethylation and reexpression of silenced tumor suppressor genes, this has not yet been proven in the clinic. 5-azaC might be acting through methylation-independent mechanisms, through induction of damage response pathways, or via toxicity associated with incorporation into DNA to induce tumor suppressor genes. It is unclear whether its clinical activity is a result of DNA methylation-independent activities mediated through 5-azaC binding of DNMT1 and other DNMTs, nor is it clear what specific DNMT isoforms are responsible for the anticancer activity of 5-azaC. Identifying the critical DNMT isotype involved would guide the development of isotypic-specific DNMT inhibitors. Understanding why 5-azaC is effective in hematological cancers is critical for developing second-generation potent

and less toxic DNA methylation inhibitors. These unresolved issues also have implications for the dosing and scheduling of 5-azaC. Under the supposition that 5-azaC causes demethylation at low doses, whereas it is mainly toxic at high doses, researchers in recent trials have focused on doses of 5-azaC that are well below the maximum tolerated dose (MTD) (122). These trials showed better responses than previous trials, but there was no immediate correlation between the response past a given threshold and the extent of demethylation. The response was not correlated with the presence of a hypermethylated *P15* prior to treatment, which served as a readout for the state of tumor suppressor gene methylation (122). In contrast to the hypothesis of low-dose 5-azaC for anticancer activity, a recent animal study showed that 5-azaC dose intensification increased 5-azaC antineoplastic activity (125). The issue of scheduling and dosing is a critical issue that needs to be resolved in animal testing and further clinical trials.

The only isotypic-specific DNMT1 inhibitor tested in clinical trials is MG98, a second-generation antisense oligonucleotide that specifically targets DNMT1 mRNA (126). The mechanism of action of this class of inhibitors is different from catalytic inhibitors of DNMT1. This agent eliminates the expression of DNMT1 protein entirely and thus targets all functional activities of DNMT1, including methylation-independent activities. Knockdown of DNMT1 results in inhibition of DNA replication (127), triggering of damage response (113), and induction of tumor suppressor genes (112). The immediate blockage of replication by DNMT1 knockdown dramatically limits the demethylation induced by DNMT1 inhibition, thus avoiding the potential deleterious impact of global demethylation (113). Knockdown of DNMT1 is devoid of the adverse effect of global hypomethylation. Other isotypic-specific DNMT inhibitors might exhibit different therapeutic effects in different conditions. They might enrich the arsenal and diversity of epigenetic drugs. The main issue with antisense oligonucleotides is delivery to solid tumors. Recently, the clinical trials of this class of drugs were stopped because of lack of objective response in the last phase II trials in metastatic renal cancer (128). Nevertheless, this strategy, as well as therapeutic siRNAs, carries great promise. Searching for agents that knock down DNMT1 rather than inhibit its catalytic activity is an alternative path to DNMT inhibitors that is worth pursuing.

Demethylation in Cancer and Other Diseases: Possible Adverse Effects of Inhibitors of DNA Methylation

One of the main adverse effects of catalytic inhibitors of DNA methylation enzymes is global hypomethylation. There are several lines of data to suggest that this is an undesired effect that might promote cancer metastasis and other disease states such as lupus and autoimmune disease. A recent study suggests that hypomethylation is systemic in certain cancers and could be detected even in cycling lymphocytes in bladder cancer patients (129). Demethylation activates metastatic genes such as *HEPARANASE* (130) and *uPA* and plays an important role in metastasis (131). Screens for hypomethylated genes in different cancers revealed several genes that were characteristically unmethylated in different types of cancer (132, 133). In addition to activation of gene expression through promoter demethylation, hypomethylation causes genomic instability (134) and unleashes the expression of repetitive sequences disrupting gene expression programming (135). Although knockout of *dnmt1* protected mice from colorectal cancer, *dnmt1* hypomorph alleles promoted thymic lymphomas in mice (136).

These data have important implications for DNA methylation therapy. Catalytic inhibitors of DNMTs that cause global hypomethylation, such as 5-azaC, and are now used in anticancer therapy might increase the propensity of cancer cells to metastasize. We have recently shown that treatment of non-invasive breast cancer cells with 5-azaC induces demethylation and expression of

prometastatic genes, and stimulates invasiveness (137). It is important to carefully examine whether a similar increase in metastases might occur in current clinical trials and to be cognizant of this possibility in new treatments with 5-azaC. If 5-azaC is found to stimulate metastasis in humans, this should prompt an effort to develop other classes of DNMT inhibitors, either isotypic-specific inhibitors that do not induce metastatic genes, or agents that knock down the DNMT1 protein or its interaction with the replication fork, as discussed above. DNMT inhibition is a powerful strategy to block deregulated growth of cancer cells and is worth pursuing, but it is necessary to accomplish this while avoiding the adverse effects of global hypomethylation. In this respect, it is critical to carefully examine and map the changes in gene expression profile in response to knockdown of each of the different DNMT1 isotypes.

Blocking Demethylation as a Therapeutic Strategy

An interesting therapeutic implication of the global hypomethylation observed in cancer is that inhibitors of global hypomethylation might serve as cancer therapeutics (138). It is clear, however, that we need a better understanding of the processes leading to demethylation in cancer and that this is an important field of research that requires additional input.

Two different approaches were used to block demethylation in cancer. The first approach involved treatment with the methyl donor SAM. The common sense rationale behind using SAM is that SAM is a methyl donor of all DNMT reactions and increasing cellular levels of SAM would enhance the activity of DNMT, but this obviously holds true only if the cellular concentration of SAM is well below the K_m for the different DNMTs. It is not clear that this is the case. Another proposed explanation is that increased SAM concentrations change the SAM:SAH ratio. SAH is a potent inhibitor of DNMT, therefore, by increasing SAM we reduce inhibition of DNMT and increase the rate of methylation (139). A third hypothesis is that SAM inhibits demethylation, thus tilting the equilibrium of the DNA methylation reaction toward methylation. SAM was shown to inhibit demethylase activity in vitro and in cells (68). SAM is highly unstable and it is not clear whether its in vivo activities are caused by SAM or by SAM metabolites such as 5'-methylthioadenosine (MTA) (140). MTA was recently shown to affect histone methylation as a HMTase inhibitor (141).

Notwithstanding the mechanism through which SAM induces genomic methylation, SAM was previously shown to be chemoprotective in a liver cancer model in rodents (140). In vitro treatment of human breast and prostate cancer cell lines with SAM resulted in inhibition of invasion in vitro, and metastasis and tumor growth when the cells were transplanted into nude mice in vivo (131, 142). These results call for an effort to develop SAM analogues with improved pharmacokinetics.

Another important line of investigation involves identifying proteins responsible for demethylation of metastatic genes in cancer and targeting them for inhibition. The MBD2 controversy focused on in vitro activity of MBD2 following in vitro translation of the recombinant protein (143). However, follow up data showed that transient coexpression of MBD2 and methylated promoters resulted in demethylation and activation of gene expression (144) and knockdown of MBD2-inhibited replication-independent active demethylation induced by valproate (69). Interestingly, ectopic expression of MBD2 in liver cells induced the expression of type II *HEXOKINASE*, a gene suppressed by methylation in normal liver cells and induced by demethylation in liver cancer cells (145).

Knockdown of MBD2 blocked tumor growth in vitro and in vivo (146, 147). Blocking MBD2 in breast and prostate cancer cell lines inhibits tumor growth, invasiveness, and metastasis in vivo (131, 142). Antisense oligonucleotides, siRNA inhibitors, and MBD2 antagonists are therefore potential promising antimetastatic candidates.

DNA Methylation and Demethylation Inhibitors in Other Diseases

The brain is now a fertile ground for DNA methylation research. Emerging data suggest that both early and adult environments affect DNA methylation in the brain, and that DNA methylation is changing in a physiological timescale during memory acquisition, thereby illustrating its dynamic nature (148–150). There are data to suggest that increased DNMT1 expression and hypermethylation of *REELIN* in the cortex might be involved in schizophrenia (151–155). Animal models have provided evidence that hypermethylation of *reelin* could be reversed by pharmacological treatment with HDACi (16, 84). DNMT inhibitors might be of therapeutic utility in schizophrenia. However, the currently approved DNA methylation inhibitor 5-azaC requires DNA synthesis for its action. 5-azaC is a prodrug that has to be phosphorylated to the tri-nucleotide form and incorporated into DNA to trap the DNMT during progression of the DNA replication fork (114, 156) (**Figure 3**). Thus, 5-azaC seems to be of essentially no utility in the brain, where a vast majority of neurons are postmitotic and do not incorporate DNA. Surprisingly, several recent studies attempted to inhibit DNA methylation in the brain using 5-azaC (157), but if this was successful it must have been accomplished through a different, yet unknown mechanism. A possible strategy to achieve demethylation is using HDACis. Indeed, TSA (158), valproate (40), and a benzamide HDACi, MS-275 (16), induced demethylation in the brain (**Figure 2**). Nevertheless, it might be valuable to develop small-molecule DNMT antagonists, which do not require incorporation into DNA and could thus serve as DNA methylation inhibitors even in postmitotic tissues.

Autoimmune diseases are an example of a health state with documented involvement of hypomethylation. Hypomethylation of the DNA in T cells is believed to drive expression of antigens and other genes that stimulate the autoimmune response in lupus (159–162). It was recently shown that DNA in T cells from lupus patients were hypomethylated and, interestingly, the level of hypomethylation correlated with the levels of expression of MBD2 (163). MBD2 inhibitors might be of interest in the treatment of lupus and perhaps other autoimmune diseases. In addition, it might be worthwhile to test whether SAM or MTA would be effective. A similar approach might be of value in other autoimmune and hyperinflammatory diseases.

SUMMARY AND PERSPECTIVES

In summary, chromatin modification and DNA methylation and demethylation machineries are attractive therapeutic targets in cancer and other diseases, however, certain cardinal issues need to be addressed before the full potential in therapy is realized. First, the epigenetic machinery is complex. It is therefore important to understand the differential role of specific isotypes of all the participants (HDACs, HMTases, DNMTs, and demethylases) in the specific disease in question.

Second, disease-specific changes in DNA methylation or histone modification require targeting of histone and DNA modification enzymes to specific genes by specific factors. Targeting these factors is an interesting possibility for drug development.

Third, it is important to understand the exact mechanism through which certain DNA and histone modifying enzymes promote disease. Some of the epigenetic proteins such as DNMT1 are multifunctional proteins. The bona fide enzymatic function might not be exclusively involved in transformation. It is clear, for example, that DNMT1 is involved in cancer through DNA methylation-independent and -dependent mechanisms (95, 112).

Fourth, in addition to DNMTs, the DNA demethylation machinery is emerging as a new target for inhibition of metastasis, one of the most intractable facets of cancer, and for other diseases such as autoimmune disease. The fifth issue relates to the interrelationship between the DNA methylation and chromatin modification machineries. This has several implications. First,

adverse and long-term effects through DNA methylation changes need to be considered. Second, HDACis could be used as a strategy to block DNA methylation in postmitotic tissues. Third, different combinations of histone and DNA modification inhibitors have synergistic effects, thus providing a promising approach in therapy (164).

Fourth, the emerging importance of DNA methylation in the brain and in mental health calls for the development of DNMT inhibitors that do not require DNA replication for their mode of action. Understanding how some epigenetic agents might act as psychiatric drugs is one of the most exciting new directions in epigenetics.

Although many questions remain open, the DNA methylation and chromatin modification machineries appear to be extremely important targets for novel therapeutics that are bound to have an impact on human disease. These classes of drugs will open new chapters in pharmacology and in our therapeutic arsenal.

DISCLOSURE STATEMENT

The author has received funding grants and patents that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS

The studies in Moshe Szyf's lab were supported by the National Cancer Institute of Canada and the Canadian Institute of Health Research.

LITERATURE CITED

1. Razin A. 1998. CpG methylation, chromatin structure and gene silencing—a three-way connection. *EMBO J.* 17:4905–8
2. Bergmann A, Lane ME. 2003. Hidden targets of microRNAs for growth control. *Trends Biochem. Sci.* 28:461–63
3. Zhang B, Pan X, Cobb GP, Anderson TA. 2007. microRNAs as oncogenes and tumor suppressors. *Dev. Biol.* 302:1–12
4. Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, et al. 2005. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. *Proc. Natl. Acad. Sci. USA* 102:16426–31
5. Vu TH, Jirtle RL, Hoffman AR. 2006. Cross-species clues of an epigenetic imprinting regulatory code for the IGF2R gene. *Cytogenet. Genome Res.* 113:202–8
6. Lee JT, Strauss WM, Dausman JA, Jaenisch R. 1996. A 450 kb transgene displays properties of the mammalian X-inactivation center. *Cell* 86:83–94
7. Saito Y, Jones PA. 2006. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. *Cell Cycle* 5:2220–22
8. Finch JT, Lutter LC, Rhodes D, Brown RS, Rushton B, et al. 1977. Structure of nucleosome core particles of chromatin. *Nature* 269:29–36
9. Sarma K, Reinberg D. 2005. Histone variants meet their match. *Nat. Rev. Mol. Cell Biol.* 6:139–49
10. Jenuwein T. 2001. Re-SET-ting heterochromatin by histone methyltransferases. *Trends Cell Biol.* 11:266–73
11. Wade PA, Pruss D, Wolffe AP. 1997. Histone acetylation: chromatin in action. *Trends Biochem. Sci.* 22:128–32
12. Shiio Y, Eisenman RN. 2003. Histone sumoylation is associated with transcriptional repression. *Proc. Natl. Acad. Sci. USA* 100:13225–30
13. Shilatifard A. 2006. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. *Annu. Rev. Biochem.* 75:243–69

14. Bolden JE, Peart MJ, Johnstone RW. 2006. Anticancer activities of histone deacetylase inhibitors. *Nat. Rev. Drug Discov.* 5:769–84
15. Rasheed WK, Johnstone RW, Prince HM. 2007. Histone deacetylase inhibitors in cancer therapy. *Expert Opin. Investig. Drugs* 16:659–78
16. Simonini MV, Camargo LM, Dong E, Maloku E, Veldic M, et al. 2006. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. *Proc. Natl. Acad. Sci. USA* 103:1587–92
17. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, et al. 2008. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. *Mol. Cancer Ther.* 7:759–68
18. Xu WS, Parmigiani RB, Marks PA. 2007. Histone deacetylase inhibitors: molecular mechanisms of action. *Oncogene* 26:5541–52
19. Duvic M, Vu J. 2007. Vorinostat in cutaneous T-cell lymphoma. *Drugs Today (Barc.)* 43:585–99
20. Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, et al. 2008. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. *J. Clin. Oncol.* 26:1940–47
21. Kell J. 2007. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer. *Curr. Opin. Investig. Drugs* 8:485–92
22. Blumenberg M, Gao S, Dickman K, Grollman AP, Bottinger EP, Zavadil J. 2007. Chromatin structure regulation in transforming growth factor-beta-directed epithelial-mesenchymal transition. *Cells Tissues Organs* 185:162–74
23. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, et al. 1997. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. *Biochem. Biophys. Res. Commun.* 241:142–50
24. Ou JN, Torrisani J, Unterberger A, Provencal N, Shikimi K, et al. 2007. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. *Biochem. Pharmacol.* 73:1297–307
25. Yoshida M, Kijima M, Akita M, Beppu T. 1990. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. *J. Biol. Chem.* 265:17174–79
26. Marks PA, Richon VM, Rifkind RA. 2000. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. *J. Natl. Cancer Inst.* 92:1210–16
27. Yoshikawa M, Hishikawa K, Marumo T, Fujita T. 2007. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. *J. Am. Soc. Nephrol.* 18:58–65
28. McGarry LC, Winnie JN, Ozanne BW. 2004. Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. *Oncogene* 23:5284–92
29. Weaver IC, Meaney MJ, Szyf M. 2006. Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. *Proc. Natl. Acad. Sci. USA* 103:3480–85
30. Dannenberg LO, Edenberg HJ. 2006. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. *BMC Genomics* 7:181
31. Chiba T, Yokosuka O, Arai M, Tada M, Fukai K, et al. 2004. Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. *J. Hepatol.* 41:436–45
32. Lee HS, Park MH, Yang SJ, Jung HY, Byun SS, et al. 2004. Gene expression analysis in human gastric cancer cell line treated with trichostatin A and S-adenosyl-L-homocysteine using cDNA microarray. *Biol. Pharm. Bull.* 27:1497–503
33. Peinado H, Ballestar E, Esteller M, Cano A. 2004. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. *Mol. Cell. Biol.* 24:306–19
34. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK. 2003. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. *Biochem. Biophys. Res. Commun.* 310:529–36

35. Alarcon JM, Malleret G, Touzani K, Vronskaya S, Ishii S, et al. 2004. Chromatin acetylation, memory, and LTP are impaired in CBP \pm mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. *Neuron* 42:947-59
36. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. 2001. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. *J. Biol. Chem.* 276:36734-41
37. Yoshimura R, Shinkai K, Ueda N, Nakamura J. 2007. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients. *Pharmacopsychiatry* 40:9-13
38. Bowden CL. 2007. Spectrum of effectiveness of valproate in neuropsychiatry. *Expert Rev. Neurother.* 7:9-16
39. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. 2007. Recovery of learning and memory is associated with chromatin remodelling. *Nature* 447:178-82
40. Dong E, Guidotti A, Grayson DR, Costa E. 2007. Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. *Proc. Natl. Acad. Sci. USA* 104:4676-81
41. Sharma RP, Rosen C, Kartan S, Guidotti A, Costa E, et al. 2006. Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population. *Schizophr. Res.* 88:227-31
42. Basan A, Leucht S. 2004. Valproate for schizophrenia. *Cochrane Database Syst. Rev.* 1:CD004028
43. Citrome L, Shope CB, Nolan KA, Czobor P, Volavka J. 2007. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. *Int. Clin. Psychopharmacol.* 22:356-62
44. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, et al. 2007. Deacetylase inhibition promotes the generation and function of regulatory T cells. *Nat. Med.* 13:1299-307
45. Johnson J, Pahuja A, Graham M, Hering B, Hancock WW, Bansal-Pakala P. 2008. Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques. *Transpl. Proc.* 40:459-61
46. McGee SL, Hargreaves M. 2006. Exercise and skeletal muscle glucose transporter 4 expression: molecular mechanisms. *Clin. Exp. Pharmacol. Physiol.* 33:395-99
47. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, et al. 2002. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. *Cancer Res.* 62:6456-61
48. Coombes MM, Briggs KL, Bone JR, Clayman GL, El-Naggar AK, Dent SY. 2003. Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation. *Oncogene* 22:8902-11
49. Meng CF, Zhu XJ, Peng G, Dai DQ. 2007. Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines. *World J. Gastroenterol.* 13:6166-71
50. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, et al. 2007. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for *de novo* methylation in cancer. *Nat. Genet.* 39:232-36
51. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. 2005. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. *Nat. Chem. Biol.* 1:143-45
52. Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, et al. 2007. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. *Mol. Cell* 25:473-81
53. Holbert MA, Marmorstein R. 2005. Structure and activity of enzymes that remove histone modifications. *Curr. Opin. Struct. Biol.* 15:673-80
54. Shi Y, Lan F, Matson C, Mulligan P, Whetstone JR, et al. 2004. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell* 119:941-53
55. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, et al. 2007. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. *Proc. Natl. Acad. Sci. USA* 104:8023-28
56. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhhattar R. 2006. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. *Chem. Biol.* 13:563-67
57. Razin A, Riggs AD. 1980. DNA methylation and gene function. *Science* 210:604-10

58. Razin A, Cedar H. 1977. Distribution of 5-methylcytosine in chromatin. *Proc. Natl. Acad. Sci. USA* 74:2725–28
59. Comb M, Goodman HM. 1990. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. *Nucleic Acids Res.* 18:3975–82
60. Inamdar NM, Ehrlich KC, Ehrlich M. 1991. CpG methylation inhibits binding of several sequence-specific DNA-binding proteins from pea, wheat, soybean and cauliflower. *Plant Mol. Biol.* 17:111–23
61. Nan X, Campoy FJ, Bird A. 1997. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. *Cell* 88:471–81
62. Hendrich B, Bird A. 1998. Identification and characterization of a family of mammalian methyl-CpG binding proteins. *Mol. Cell. Biol.* 18:6538–47
63. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, et al. 1999. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. *Nat. Genet.* 23:58–61
64. Fujita N, Takebayashi S, Okumura K, Kudo S, Chiba T, et al. 1999. Methylation-mediated transcriptional silencing in euchromatin by methyl-CpG binding protein MBD1 isoforms. *Mol. Cell. Biol.* 19:6415–26
65. Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. 1999. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. *Genes Dev.* 13:1924–35
66. Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A. 1999. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. *Nature* 401:301–4
67. Hamm S, Just G, Lacoste N, Moitessier N, Szyf M, Mamer O. 2008. On the mechanism of demethylation of 5-methylcytosine in DNA. *Bioorg. Med. Chem. Lett.* 18:1046–49
68. Detich N, Hamm S, Just G, Knox JD, Szyf M. 2003. The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. *J. Biol. Chem.* 278:20812–20
69. Detich N, Bovenzi V, Szyf M. 2003. Valproate induces replication-independent active DNA demethylation. *J. Biol. Chem.* 278:27586–92
70. Cervoni N, Szyf M. 2001. Demethylase activity is directed by histone acetylation. *J. Biol. Chem.* 276:40778–87
71. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. 1999. A mammalian protein with specific demethylase activity for mCpG DNA. *Nature* 397:579–83
72. Okano M, Xie S, Li E. 1998. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases [letter]. *Nat. Genet.* 19:219–20
73. Ramchandani S, Bhattacharya SK, Cervoni N, Szyf M. 1999. DNA methylation is a reversible biological signal. *Proc. Natl. Acad. Sci. USA* 96:6107–12
74. Miller CA, Sweatt JD. 2007. Covalent modification of DNA regulates memory formation. *Neuron* 53:857–69
75. Metivier R, Gallais R, Tiffoche C, Le Peron C, Jurkowska RZ, et al. 2008. Cyclical DNA methylation of a transcriptionally active promoter. *Nature* 452:45–50
76. Jost JP. 1993. Nuclear extracts of chicken embryos promote an active demethylation of DNA by excision repair of 5-methyldeoxycytidine. *Proc. Natl. Acad. Sci. USA* 90:4684–88
77. Zhu B, Zheng Y, Hess D, Anglikler H, Schwarz S, et al. 2000. 5-methylcytosine-DNA glycosylase activity is present in a cloned G/T mismatch DNA glycosylase associated with the chicken embryo DNA demethylation complex. *Proc. Natl. Acad. Sci. USA* 97:5135–39
78. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. 1999. A mammalian protein with specific demethylase activity for mCpG DNA. *Nature* 397:579–83
79. Barreto G, Schäfer A, Marhold J, Stach D, Swaminathan SK, et al. 2007. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. *Nature* 445:671–75
80. Jin SG, Guo C, Pfeifer GP. 2008. GADD45A does not promote DNA demethylation. *PLoS Genet.* 4:e1000013
81. Kangaspeska S, Stride B, Metivier R, Polycarpou-Schwarz M, Ibberson D, et al. 2008. Transient cyclical methylation of promoter DNA. *Nature* 452:112–15
82. D'Alessio AC, Szyf M. 2006. Epigenetic tete-a-tete: the bilateral relationship between chromatin modifications and DNA methylation. *Biochem. Cell Biol.* 84:463–76

83. Milutinovic S, D'Alessio AC, Detich N, Szyf M. 2007. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. *Carcinogenesis* 28:560–71
84. Tremolizzo L, Carboni G, Ruzicka WB, Mitchell CP, Sugaya I, et al. 2002. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. *Proc. Natl. Acad. Sci. USA* 99:17095–100
85. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. 2000. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. *Nat. Genet.* 24:88–91
86. Rountree MR, Bachman KE, Baylin SB. 2000. DNMT1 binds HDAC2 and a new corepressor, DMAP1, to form a complex at replication foci. *Nat. Genet.* 25:269–77
87. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. 2003. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. *J. Biol. Chem.* 278:4035–40
88. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. 2006. The Polycomb group protein EZH2 directly controls DNA methylation. *Nature* 439:871–74
89. Smallwood A, Esteve PO, Pradhan S, Carey M. 2007. Functional cooperation between HP1 and DNMT1 mediates gene silencing. *Genes Dev.* 21:1169–78
90. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, et al. 2007. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. *Proc. Natl. Acad. Sci. USA* 104(13):5527–32
91. MacLeod AR, Rouleau J, Szyf M. 1995. Regulation of DNA methylation by the Ras signaling pathway. *J. Biol. Chem.* 270:11327–37
92. Slack A, Cervoni N, Pinard M, Szyf M. 1999. DNA methyltransferase is a downstream effector of cellular transformation triggered by simian virus 40 large T antigen. *J. Biol. Chem.* 274:10105–12
93. Bigey P, Ramchandani S, Theberge J, Araujo FD, Szyf M. 2000. Transcriptional regulation of the human DNA Methyltransferase (dnmt1) gene. *Gene* 242:407–18
94. Szyf M. 2006. Targeting DNA methylation in cancer. *Bull. Cancer* 93:961–72
95. Szyf M, Knox DJ, Milutinovic S, Slack AD, Araujo FD. 2000. How does DNA methyltransferase cause oncogenic transformation? *Ann. NY Acad. Sci.* 910:156–77
96. D'Alessio AC, Weaver IC, Szyf M. 2007. Acetylation-induced transcription is required for active DNA demethylation in methylation-silenced genes. *Mol. Cell. Biol.* 27:7462–74
97. Lichtenstein M, Keini G, Cedar H, Bergman Y. 1994. B cell-specific demethylation: a novel role for the intronic κ chain enhancer sequence. *Cell* 76:913–23
98. Weaver IC, D'Alessio AC, Brown SE, Hellstrom IC, Dymov S, et al. 2007. The transcription factor nerve growth factor-inducible protein A mediates epigenetic programming: altering epigenetic marks by immediate-early genes. *J. Neurosci.* 27:1756–68
99. Szyf M. 1994. DNA methylation properties: consequences for pharmacology. *Trends Pharmacol. Sci.* 15:233–38
100. Jones PA, Taylor SM. 1980. Cellular differentiation, cytidine analogs and DNA methylation. *Cell* 20:85–93
101. Kuendgen A, Lubbert M. 2008. Current status of epigenetic treatment in myelodysplastic syndromes. *Ann. Hematol.* 87:601–11
102. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. 2001. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. *Hum. Mol. Genet.* 10:687–92
103. Issa JP, Vertino PM, Wu J, Sazawal S, Celano P, et al. 1993. Increased cytosine DNA-methyltransferase activity during colon cancer progression. *J. Natl. Cancer Inst.* 85:1235–40
104. Ehrlich M. 2002. DNA methylation in cancer: too much, but also too little. *Oncogene* 21:5400–13
105. Szyf M, Bozovic V, Tanigawa G. 1991. Growth regulation of mouse DNA methyltransferase gene expression. *J. Biol. Chem.* 266:10027–30
106. Torrisani J, Unterberger A, Tendulkar SR, Shikimi K, Szyf M. 2006. AUF1 cell cycle variations define genomic DNA methylation by regulation of DNMT1 mRNA stability. *Mol. Cell. Biol.* 27:395–410
107. Detich N, Ramchandani S, Szyf M. 2001. A conserved 3'-untranslated element mediates growth regulation of DNA methyltransferase 1 and inhibits its transforming activity. *J. Biol. Chem.* 276:24881–90

108. Wu J, Issa JP, Herman J, Bassett DE Jr, Nelkin BD, Baylin SB. 1993. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. *Proc. Natl. Acad. Sci. USA* 90:8891–95
109. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, et al. 1995. Suppression of intestinal neoplasia by DNA hypomethylation. *Cell* 81:197–205
110. MacLeod AR, Szyf M. 1995. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis. *J. Biol. Chem.* 270:8037–43
111. Ramchandani S, MacLeod AR, Pinard M, von Hofe E, Szyf M. 1997. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. *Proc. Natl. Acad. Sci. USA* 94:684–89
112. Milutinovic S, Knox JD, Szyf M. 2000. DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1). *J. Biol. Chem.* 275:6353–59
113. Unterberger A, Andrews SD, Weaver IC, Szyf M. 2006. DNA methyltransferase 1 knockdown activates a replication stress checkpoint. *Mol. Cell. Biol.* 26:7575–86
114. Wu JC, Santi DV. 1985. On the mechanism and inhibition of DNA cytosine methyltransferases. *Prog. Clin. Biol. Res.* 198:119–29
115. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, et al. 2003. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. *J. Natl. Cancer Inst.* 95:399–409
116. Juttermann R, Li E, Jaenisch R. 1994. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. *Proc. Natl. Acad. Sci. USA* 91:11797–801
117. Brueckner B, Boy RG, Siedlecki P, Musch T, Kliem HC, et al. 2005. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. *Cancer Res.* 65:6305–11
118. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. 1988. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. *J. Immunol.* 140:2197–200
119. Scheinbart LS, Johnson MA, Gross LA, Edelstein SR, Richardson BC. 1991. Procainamide inhibits DNA methyltransferase in a human T cell line. *J. Rheumatol.* 18:530–34
120. Castellano S, Kuck D, Sala M, Novellino E, Lyko F, Sbardella G. 2008. Constrained analogues of procaine as novel small molecule inhibitors of DNA methyltransferase-1. *J. Med. Chem.* 51:2321–25
121. Szyf M. 2007. The dynamic epigenome and its implications in toxicology. *Toxicol. Sci.* 100:7–23
122. Oki Y, Aoki E, Issa JP. 2007. Decitabine—bedside to bench. *Crit. Rev. Oncol. Hematol.* 61:140–52
123. Weiss AJ, Metter GE, Nealon TF, Keanan JP, Ramirez G, et al. 1977. Phase II study of 5-azacytidine in solid tumors. *Cancer Treat. Rep.* 61:55–58
124. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, et al. 2007. Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. *Blood* 110:2302–8
125. Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, et al. 2008. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. *BMC Cancer* 8:128
126. Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, et al. 2003. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. *Investig. New Drugs* 21:85–97
127. Knox JD, Araujo FD, Bigey P, Slack AD, Price GB, et al. 2000. Inhibition of DNA methyltransferase inhibits DNA replication. *J. Biol. Chem.* 275:17986–90
128. Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, et al. 2006. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. *Investig. New Drugs* 24:159–67
129. Moore LE, Pfeiffer RM, Poscablo C, Real FX, Kogevinas M, et al. 2008. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. *Lancet Oncol.* 9:359–66
130. Shteper PJ, Zcharia E, Ashhab Y, Peretz T, Vlodavsky I, Ben-Yehuda D. 2003. Role of promoter methylation in regulation of the mammalian heparanase gene. *Oncogene* 22:7737–49

131. Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA. 2004. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. *J. Biol. Chem.* 279:31735–44
132. Sato N, Fukushima N, Matsubayashi H, Goggins M. 2003. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. *Oncogene* 23:1531–38
133. Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, et al. 2008. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. *Proc. Natl. Acad. Sci. USA* 105:252–57
134. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. 1998. DNA hypomethylation leads to elevated mutation rates. *Nature* 395:89–93
135. Howard G, Eiges R, Gaudet F, Jaenisch R, Eden A. 2007. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. *Oncogene* 27:404–8
136. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, et al. 2003. Induction of tumors in mice by genomic hypomethylation. *Science* 300:489–92
137. Ateeq B, Unterberger A, Rabbani SA, Szyf M. 2008. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. *Neoplasia* 10:266–78
138. Campbell PM, Bovenzi V, Szyf M. 2004. Methylated DNA-binding protein 2 antisense inhibitors suppress tumorigenesis of human cancer cell lines in vitro and in vivo. *Carcinogenesis* 25:499–507
139. Pascale RM, Simile MM, De Miglio MR, Feo F. 2002. Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. *Alcohol* 27:193–98
140. Pascale RM, Simile MM, Satta G, Seddaiu MA, Daino L, et al. 1991. Comparative effects of L-methionine, S-adenosyl-L-methionine and 5'-methylthioadenosine on the growth of preneoplastic lesions and DNA methylation in rat liver during the early stages of hepatocarcinogenesis. *Anticancer Res.* 11:1617–24
141. Ara AI, Xia M, Ramani K, Mato JM, Lu SC. 2008. S-adenosylmethionine inhibits lipopolysaccharide-induced gene expression via modulation of histone methylation. *Hepatology* 47:1655–66
142. Shukeir N, Pakneshan P, Chen G, Szyf M, Rabbani SA. 2006. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. *Cancer Res.* 66:9202–10
143. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, et al. 1999. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. *Nat. Genet.* 23:58–61
144. Detich N, Theberge J, Szyf M. 2002. Promoter-specific activation and demethylation by MBD2/demethylase. *J. Biol. Chem.* 277:35791–94
145. Goel A, Mathupala SP, Pedersen PL. 2003. Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. *J. Biol. Chem.* 278:15333–40
146. Slack A, Bovenzi V, Bigey P, Ivanov MA, Ramchandani S, et al. 2002. Antisense MBD2 gene therapy inhibits tumorigenesis. *J. Gene Med.* 4:381–89
147. Campbell PM, Bovenzi V, Szyf M. 2003. Methylated DNA binding protein 2 antisense inhibitors suppress tumorigenesis of human cancer lines in vitro and in vivo. *Carcinogenesis* 25:499–507
148. Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S, et al. 2005. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. *J. Neurosci.* 25:11045–54
149. Meaney MJ, Szyf M. 2005. Maternal care as a model for experience-dependent chromatin plasticity? *Trends Neurosci.* 28:456–63
150. Weaver IC, Diorio J, Seckl JR, Szyf M, Meaney MJ. 2004. Early environmental regulation of hippocampal glucocorticoid receptor gene expression: characterization of intracellular mediators and potential genomic target sites. *Ann. NY Acad. Sci.* 1024:182–212
151. Costa E, Dong E, Grayson DR, Guidotti A, Ruzicka W, Veldic M. 2007. Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. *Epigenetics* 2:29–36
152. Grayson DR, Jia X, Chen Y, Sharma RP, Mitchell CP, et al. 2005. Reelin promoter hypermethylation in schizophrenia. *Proc. Natl. Acad. Sci. USA* 102:9341–46
153. Costa E, Grayson DR, Mitchell CP, Tremolizzo L, Veldic M, Guidotti A. 2003. GABAergic cortical neuron chromatin as a putative target to treat schizophrenia vulnerability. *Crit. Rev. Neurobiol.* 15:121–42

154. Costa E, Chen Y, Davis J, Dong E, Noh JS, et al. 2002. REELIN and schizophrenia: A disease at the interface of the genome and the epigenome. *Mol. Interv.* 2:47–57
155. Guidotti A, Ruzicka W, Grayson DR, Veldic M, Pinna G, et al. 2007. S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis. *NeuroReport* 18:57–60
156. Jones PA. 1985. Altering gene expression with 5-azacytidine. *Cell* 40:485–86
157. Levenson JM, Roth TL, Lubin FD, Miller CA, Huang IC, et al. 2006. Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. *J. Biol. Chem.* 281:15763–73
158. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, et al. 2004. Epigenetic programming by maternal behavior. *Nat. Neurosci.* 7:847–54
159. Richardson B, Ray D, Yung R. 2004. Murine models of lupus induced by hypomethylated T cells. *Methods Mol. Med.* 102:285–94
160. Sekigawa I, Okada M, Ogasawara H, Kaneko H, Hishikawa T, Hashimoto H. 2003. DNA methylation in systemic lupus erythematosus. *Lupus* 12:79–85
161. Richardson BC. 2002. Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. *J. Nutr.* 132:S2401–5
162. Lu Q, Kaplan M, Ray D, Ray D, Zacharek S, et al. 2002. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. *Arthritis Rheum.* 46:1282–91
163. Balada E, Ordi-Ros J, Serrano-Acedo S, Martinez-Lostao L, Vilardell-Tarres M. 2007. Transcript overexpression of the MBD2 and MBD4 genes in CD4+ T cells from systemic lupus erythematosus patients. *J. Leukoc. Biol.* 81:1609–16
164. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. *Nat. Genet.* 21:103–7



Contents

Autonomic Neurotransmission: 60 Years Since Sir Henry Dale <i>Geoffrey Burnstock</i>	1
The Role of G $\beta\gamma$ Subunits in the Organization, Assembly, and Function of GPCR Signaling Complexes <i>Denis J. Dupré, Mélanie Robitaille, R. Victor Rebois, and Terence E. Hébert</i>	31
Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics <i>Neal L. Benowitz</i>	57
Targeting Proteins for Destruction by the Ubiquitin System: Implications for Human Pathobiology <i>Alan L. Schwartz and Aaron Ciechanover</i>	73
Progress in Genetic Studies of Pain and Analgesia <i>Michael L. LaCroix-Fralish and Jeffrey S. Mogil</i>	97
Lipid Mediators in Health and Disease: Enzymes and Receptors as Therapeutic Targets for the Regulation of Immunity and Inflammation <i>Takao Shimizu</i>	123
Sorting out Astrocyte Physiology from Pharmacology <i>Todd A. Fiacco, Cendra Agulbon, and Ken D. McCarthy</i>	151
Lithium's Antisuiicidal Efficacy: Elucidation of Neurobiological Targets Using Endophenotype Strategies <i>Colleen E. Kovacsics, Irving I. Gottesman, and Todd D. Gould</i>	175
Global and Site-Specific Quantitative Phosphoproteomics: Principles and Applications <i>Boris Macek, Matthias Mann, and Jesper V. Olsen</i>	199
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy <i>Sanjeev Shangary and Shaomeng Wang</i>	223

Epigenetics, DNA Methylation, and Chromatin Modifying Drugs <i>Moshe Szyf</i>	243
The COXIB Experience: A Look in the Rearview Mirror <i>Lawrence J. Marnett</i>	265
Quantitative Disease, Drug, and Trial Models <i>Jogarao V.S. Gobburu and Lawrence J. Lesko</i>	291
Immunodrugs: Therapeutic VLP-Based Vaccines for Chronic Diseases <i>Gary T. Jennings and Martin F. Bachmann</i>	303
Akt/GSK3 Signaling in the Action of Psychotropic Drugs <i>Jean-Martin Beaulieu, Raul R. Gainetdinov, and Marc G. Caron</i>	327
Topical Microbicides to Prevent HIV: Clinical Drug Development Challenges <i>Craig W. Hendrix, Ying Jun Cao, and Edward J. Fuchs</i>	349
Emerging Pharmacology: Inhibitors of Human Immunodeficiency Virus Integration <i>Daria Hazuda, Marian Iwamoto, and Larissa Wenning</i>	377
The TRPC Class of Ion Channels: A Critical Review of Their Roles in Slow, Sustained Increases in Intracellular Ca ²⁺ Concentrations <i>Lutz Birnbaumer</i>	395
Mycobacterial Subversion of Chemotherapeutic Reagents and Host Defense Tactics: Challenges in Tuberculosis Drug Development <i>Liem Nguyen and Jean Pieters</i>	427
Indexes	
Contributing Authors, Volumes 45–49	455
Chapter Titles, Volumes 45–49	458
Errata	
An online log of corrections to <i>Annual Review of Pharmacology and Toxicology</i> articles may be found at http://pharmtox.annualreviews.org/errata.shtml	